Anti-obesity drugs can shrink more than patients
Starry-eyed venture capitalists love to talk about how promising startups might capture a chunk of a giant total addressable market (TAM). New anti-obesity drugs have the potential to transform public health, while obliterating demand for products and services from the medical, food and fitness industries. Drugs developed by Novo Nordisk and Eli Lilly appear to be the first truly effective diet treatments.